Literature DB >> 31702480

Emerging CAR T cell therapies: clinical landscape and patent technological routes.

Virgínia Picanco-Castro1, Cristiano Gonçalves Pereira2, Kamilla Swiech1,3, Kelen Cristina Ribeiro Malmegrim1,3, Dimas Tadeu Covas1, Geciane Silveira Porto2,4.   

Abstract

The purpose of this study is to mine CAR-T patents and therapies under development, to design a landscape of the sector and to understand key therapy segments and their current trends. The study analyzed the entire market, consisting of 1624 patent families and 509 biologics under development, to depict an overview of the CAR-T therapies and their state of the art. Our results showed cutting-edge inventions, the major players, the dynamics of cooperation among institutions, the progress of the therapies' generation over the years and future innovation pathways. CAR-T therapies are transforming the current scenario for cancer treatment, and this study reveals the picture of what we can likely expect ahead in order to assist scientists at the academy and industry to improve their research strategies.

Entities:  

Keywords:  CAR-T cells; Patent landscape; clinical trials; technology forecasting

Year:  2019        PMID: 31702480      PMCID: PMC7482707          DOI: 10.1080/21645515.2019.1689744

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  23 in total

1.  T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Authors:  Michael Kalos; Bruce L Levine; David L Porter; Sharyn Katz; Stephan A Grupp; Adam Bagg; Carl H June
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

2.  Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma.

Authors:  P K Darcy; M H Kershaw; J A Trapani; M J Smyth
Journal:  Eur J Immunol       Date:  1998-05       Impact factor: 5.532

3.  Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.

Authors:  Stephen P Hunger; Xiaomin Lu; Meenakshi Devidas; Bruce M Camitta; Paul S Gaynon; Naomi J Winick; Gregory H Reaman; William L Carroll
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

4.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

Authors:  Barbara Savoldo; Carlos Almeida Ramos; Enli Liu; Martha P Mims; Michael J Keating; George Carrum; Rammurti T Kamble; Catherine M Bollard; Adrian P Gee; Zhuyong Mei; Hao Liu; Bambi Grilley; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner; Gianpietro Dotti
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

Review 5.  CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.

Authors:  R H Scheuermann; E Racila
Journal:  Leuk Lymphoma       Date:  1995-08

Review 6.  Engineered T cells for cancer therapy.

Authors:  Carl H June; Marcela V Maus; Gabriela Plesa; Laura A Johnson; Yangbing Zhao; Bruce L Levine; Stephan A Grupp; David L Porter
Journal:  Cancer Immunol Immunother       Date:  2014-06-19       Impact factor: 6.968

Review 7.  Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.

Authors:  Marcela V Maus; Bruce L Levine
Journal:  Oncologist       Date:  2016-03-23

8.  Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.

Authors:  Lihua E Budde; Carolina Berger; Yukang Lin; Jinjuan Wang; Xubin Lin; Shani E Frayo; Shaunda A Brouns; David M Spencer; Brian G Till; Michael C Jensen; Stanley R Riddell; Oliver W Press
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

Review 9.  Clinical application of genetically modified T cells in cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Clare Y Slaney; Phillip K Darcy
Journal:  Clin Transl Immunology       Date:  2014-05-16

Review 10.  CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products.

Authors:  Julio C Chavez; Christina Bachmeier; Mohamed A Kharfan-Dabaja
Journal:  Ther Adv Hematol       Date:  2019-04-15
View more
  3 in total

1.  Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.

Authors:  Raphaëlle Toledano Zur; Galit Adler; Katerina Shamalov; Yair Tal; Chen Ankri; Cyrille J Cohen
Journal:  Exp Suppl       Date:  2022

2.  CAR-based cell therapy: evaluation with bibliometrics and patent analysis.

Authors:  Yajun Yuan; Qihan Fu; Yaqun Zhang; Danhai Xu; Yeqing Wu; Qiufei Qiu; Wuyuan Zhou
Journal:  Hum Vaccin Immunother       Date:  2021-06-29       Impact factor: 4.526

3.  A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors.

Authors:  Julie K Fierle; Johan Abram-Saliba; Vasileios Atsaves; Matteo Brioschi; Mariastella de Tiani; Patrick Reichenbach; Melita Irving; George Coukos; Steven M Dunn
Journal:  Sci Rep       Date:  2022-01-21       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.